MUSC Hollings Cancer Center
MUSC Hollings Cancer Center
Charleston, South Carolina, United States9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, otorhinolaryngologic disease, squamous cell carcinoma | Recruiting | Phase 3 | 2026-10-08 | NCT07768189 | |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT07293351 | |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-22 | NCT06855277 | |
| Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, kidney cancer, kidney disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, stomach disorder, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-09 | NCT06750185 | |
| WATER IV PCa (AS Sub-study) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Not applicable | 2026-08-04 | NCT07650448 | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, sarcoma, skin disorder, skin neoplasm, squamous cell carcinoma | Active, not recruiting | Early phase 1 | 2026-05-22 | NCT04541108 | |
| WATER IV Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Not applicable | 2026-05-04 | NCT06651632 | |
| A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia | Body Weight, Body Weight Changes, Cachexia, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Thinness, Weight Loss | Recruiting | Phase 1 | 2026-01-08 | NCT05865535 | |
| A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Higher-risk Myelodysplastic Syndromes | Recruiting | Phase 2 | 2025-02-11 | NCT06196203 |